Literature DB >> 21524697

Evaluation of Lysimachia christinae Hance extracts as anticholecystitis and cholagogic agents in animals.

Xian Yang1, Bo-Chu Wang, Xue Zhang, Wei-Qi Liu, Jun-Zhen Qian, Wei Li, Jia Deng, Gurinder K Singh, Hui Su.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Lysimachia christinae Hance is one of the herbs commonly used in traditional Chinese medicine for the treatment of cholecystitis and cholagogic efficiency. AIMS OF THE STUDY: The water extract of Lysimachia christinae Hance was investigated to see if it possesses cholecystitis and cholagogic effects through traditional pathways.
MATERIALS AND METHODS: Lithocholic acid (LCA) and Escherichia coli were used to induce cholecystitis in adult guinea pigs. The present study evaluated the cholagogic effects of LCHE treatment on bile secretion and bile emptying in Sprague-Dawley rats and male Kunming mice.
RESULTS: The results showed that LCHE not only produced excellent anticholecystitis effects but also improved lesion severity in gallbladders induced by LCA. Similarly, LCHE administered to animals in the high-dose group exhibited an antibacterial effect in acute cholecystitis, and treatment with a mid-range or a high dose of LCHE resulted in an antipyretic effect, however, three doses of LCHE treatment groups had no effect on pathological change induced by Escherichia coli in gallbladder. Treatment with a high dose of LCHE significantly promoted bile secretion (0-90min, P<0.01), and treatment with a mid-range dose also significantly promoted bile secretion (30-60min P<0.05). Furthermore, treatment with a high dose of LCHE significantly promoted bile emptying (P<0.01).
CONCLUSIONS: Our results demonstrate that LCHE exhibits a marked anticholecystitis and cholagogic activity in animals, which supports previous claims of its use in traditional Chinese medicine.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21524697     DOI: 10.1016/j.jep.2011.04.029

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  7 in total

1.  Water Extract of Lysimachia christinae Inhibits Trabecular Bone Loss and Fat Accumulation in Ovariectomized Mice.

Authors:  Ki-Shuk Shim; Youn-Hwan Hwang; Seon-A Jang; Taesoo Kim; Hyunil Ha
Journal:  Nutrients       Date:  2020-06-29       Impact factor: 5.717

2.  Detoxication mechanisms of Radix Tripterygium wilfordii via compatibility with Herba Lysimachia christinae in S180-bearing mice by involving Nrf2.

Authors:  Jun-Ming Wang; Hong Cai; Jin-Hua Li; Rong-Xing Chen; Yue-Yue Zhang; Jin-Yang Li; Ning-Ning Ding; Chen Liu; Ying Cui
Journal:  Biosci Rep       Date:  2018-07-12       Impact factor: 3.840

Review 3.  The phytochemistry, pharmacology and traditional medicinal use of Glechomae Herba - a systematic review.

Authors:  Liu Yang; Jiaxu Zhang; Senwang Zheng; Ajiao Hou; Song Wang; Huan Yu; Xuejiao Wang; Yingjie Xu; Haixue Kuang; Hai Jiang
Journal:  RSC Adv       Date:  2021-05-27       Impact factor: 4.036

Review 4.  The Effect of Lithocholic Acid on the Gut-Liver Axis.

Authors:  Wei Sheng; Guang Ji; Li Zhang
Journal:  Front Pharmacol       Date:  2022-07-07       Impact factor: 5.988

5.  Traditional Therapies Used to Manage Diabetes and Related Complications in Mauritius: A Comparative Ethnoreligious Study.

Authors:  M Fawzi Mahomoodally; A Mootoosamy; S Wambugu
Journal:  Evid Based Complement Alternat Med       Date:  2016-04-21       Impact factor: 2.629

6.  Evaluation of the antioxidant and endothelial protective effects of Lysimachia christinae Hance (Jin Qian Cao) extract fractions.

Authors:  Ning-Hua Wu; Zhi-Qiang Ke; Shan Wu; Xiao-Song Yang; Qing-Jie Chen; Sheng-Tang Huang; Chao Liu
Journal:  BMC Complement Altern Med       Date:  2018-04-10       Impact factor: 3.659

7.  Neuroprotective Activity of Methanolic Extract of Lysimachia christinae against Glutamate Toxicity in HT22 Cell and Its Protective Mechanisms.

Authors:  Gahee Ryu; Choong Je Ma
Journal:  Evid Based Complement Alternat Med       Date:  2020-01-13       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.